Literature DB >> 32487680

PD-1 Blockade in Chinese versus Western Patients with Melanoma.

Alexander N Shoushtari1,2, Riyue Bao3,4, Jason J Luke5,4.   

Abstract

In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations. This work suggests future avenues for investigating mechanisms of melanoma formation and resistance to PD-1 blockade.See related article by Tang et al., p. 4250. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 32487680      PMCID： PMC7442612          DOI： 10.1158/1078-0432.CCR-20-1558

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  9 in total

1.  Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.

Authors:  Bixia Tang; Zhihong Chi; Yingbo Chen; Xiufeng Liu; Di Wu; Jing Chen; Xin Song; Weifeng Wang; Lihou Dong; Haifeng Song; Hai Wu; Hui Feng; Sheng Yao; Shuikui Qin; Xiaoshi Zhang; Jun Guo
Journal:  Clin Cancer Res       Date:  2020-04-22       Impact factor: 12.531

2.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy.

Authors:  Galina G Lagos; Benjamin Izar; Naiyer A Rizvi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-03

4.  The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Authors:  Alexander N Shoushtari; Rodrigo R Munhoz; Deborah Kuk; Patrick A Ott; Douglas B Johnson; Katy K Tsai; Suthee Rapisuwon; Zeynep Eroglu; Ryan J Sullivan; Jason J Luke; Tara C Gangadhar; April K S Salama; Varina Clark; Clare Burias; Igor Puzanov; Michael B Atkins; Alain P Algazi; Antoni Ribas; Jedd D Wolchok; Michael A Postow
Journal:  Cancer       Date:  2016-08-17       Impact factor: 6.860

5.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Authors:  Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin
Journal:  Lancet Oncol       Date:  2015-03-18       Impact factor: 41.316

6.  MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.

Authors:  Xue Bai; Yan Kong; Zhihong Chi; Xinan Sheng; Chuanliang Cui; Xuan Wang; Lili Mao; Bixia Tang; Siming Li; Bin Lian; Xieqiao Yan; Li Zhou; Jie Dai; Jun Guo; Lu Si
Journal:  Clin Cancer Res       Date:  2017-07-18       Impact factor: 12.531

7.  Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Authors:  Omid Hamid; Igor Puzanov; Reinhard Dummer; Jacob Schachter; Adil Daud; Dirk Schadendorf; Christian Blank; Lee D Cranmer; Caroline Robert; Anna C Pavlick; Rene Gonzalez; F Stephen Hodi; Paolo A Ascierto; April K S Salama; Kim A Margolin; Tara C Gangadhar; Ziwen Wei; Scot Ebbinghaus; Nageatte Ibrahim; Antoni Ribas
Journal:  Eur J Cancer       Date:  2017-11       Impact factor: 9.162

8.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Authors:  Razvan Cristescu; Robin Mogg; Mark Ayers; Andrew Albright; Erin Murphy; Jennifer Yearley; Xinwei Sher; Xiao Qiao Liu; Hongchao Lu; Michael Nebozhyn; Chunsheng Zhang; Jared K Lunceford; Andrew Joe; Jonathan Cheng; Andrea L Webber; Nageatte Ibrahim; Elizabeth R Plimack; Patrick A Ott; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan; Joanne E Tomassini; Andrey Loboda; David Kaufman
Journal:  Science       Date:  2018-10-12       Impact factor: 47.728

9.  Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Authors:  David Liu; Bastian Schilling; Derek Liu; Antje Sucker; Elisabeth Livingstone; Livnat Jerby-Arnon; Lisa Zimmer; Ralf Gutzmer; Imke Satzger; Carmen Loquai; Stephan Grabbe; Natalie Vokes; Claire A Margolis; Jake Conway; Meng Xiao He; Haitham Elmarakeby; Felix Dietlein; Diana Miao; Adam Tracy; Helen Gogas; Simone M Goldinger; Jochen Utikal; Christian U Blank; Ricarda Rauschenberg; Dagmar von Bubnoff; Angela Krackhardt; Benjamin Weide; Sebastian Haferkamp; Felix Kiecker; Ben Izar; Levi Garraway; Aviv Regev; Keith Flaherty; Annette Paschen; Eliezer M Van Allen; Dirk Schadendorf
Journal:  Nat Med       Date:  2019-12-02       Impact factor: 53.440
  9 in total
  5 in total

1.  Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis.

Authors:  Shuang Wu; Chuanping Yuan; Lei Chen; Lanlan Guo; Yong Chen; Zhenwei Peng; Lixia Lu
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

2.  Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.

Authors:  Yoon Suk Lee; Jong-Chan Lee; Jae-Hyeong Kim; Jaihwan Kim; Jin-Hyeok Hwang
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

3.  Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.

Authors:  Zixu Gao; Lu Wang; Zhengqing Song; Ming Ren; Yang Yang; Jianrui Li; Kangjie Shen; Yinlam Li; Yiteng Ding; Yanwen Yang; Yuhong Zhou; Chuanyuan Wei; Jianying Gu
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

Review 4.  Advanced Acral Melanoma Therapies: Current Status and Future Directions.

Authors:  Yiqun Zhang; Shijie Lan; Di Wu
Journal:  Curr Treat Options Oncol       Date:  2022-09-20

Review 5.  Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.

Authors:  Lili Mao; Zhonghui Qi; Li Zhang; Jun Guo; Lu Si
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.